333PFT, Senior Scientist / Scientist, Genome editing & next generation sequencing, Molecular Engineering

Job Code 333PFT

Description

Fate Therapeutics is currently seeking a talented and motivated individual with expertise in molecular biology to join a multidisciplinary team dedicated to discovery and productization of novel off-the-shelf cell-based immunotherapies. Initially the candidate will perform molecular cloning, genome editing, and next generation sequencing (NGS) to support Fate’s gene editing platform and preclinical pipelines. The position will evolve to include establishment of genomic analysis tools for NGS assays used in the manufacturing process and characterization of genetically engineered induced pluripotent stem cells (iPSCs). Candidate is highly desired to master molecular biology techniques and to independently design and deliver high quality results to meet Fate’s aggressive timelines. This is a full-time position and is located at the company’s corporate headquarters in San Diego.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 333PFT.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.